Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 31 Oct 24 424B5 Prospectus supplement for primary offering
- 8 Jul 24 424B5 Prospectus supplement for primary offering
- 8 Apr 24 424B5 Prospectus supplement for primary offering
- 11 Oct 23 424B5 Prospectus supplement for primary offering
- 11 May 23 EFFECT Notice of effectiveness
- 8 May 23 S-3/A Shelf registration (amended)
-
10 Mar 23 S-3 Shelf registration
BNGO similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 9, 2023, relating to the consolidated financial statements of Bionano Genomics, Inc. (the “Company”), appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
San Diego, California
March 10, 2023